Portal hemodynamic effects of Sacubitril valsartan in liver disease patients with hart failure: a prospective cohort study

Portal hemodynamic effects of Sacubitril valsartan in liver disease patients with hart failure: a prospective cohort study - Portal hemodynamic effects of Sacubitril valsartan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044690

Enrollment

100

Registered

2021-06-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver disease patients with hart failure

Interventions

Start Sacubitril valsartan at 50 mg twice daily and double the dose within 56days, as tolerated by the patient.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic liver disuse with heart failure

Exclusion criteria

Exclusion criteria: 1) Patients with history of hypersensitivity to any of the other ingredients of Sacubitril valsartan 2)Under administration of angiotensin converting enzyme inhibitor 3)History of angioedema 4)History of severe liver disease(Child-Pugh C) 5)Pregnancy or possibility of pregnancy 6)Patients judged as inadequate at the discretion of physicians 7)Patients not approving the study consent

Design outcomes

Primary

Measure	Time frame
Changes in portal venous area	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology, Internal Medicine

kiruha@kitasato-u.ac.jp+81-42-778-7750

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026